Source: Annual Congress 2002 - Lung cancer: treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. P. Sculier, J. J. Lafitte, J. Lecomte, T. Berghmans, J. Thiriaux, O. Van Cutsem, A. Eremidis, V. Ninane, M. Paesmans, J. Klastersky (Brussels, Charleroi, Namur, Belgium; Lille, France; Athens, Greece). A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Eur Respir J 2002; 20: Suppl. 38, 2539

Member's Comments

No comment yet.

Related content which might interest you: Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006 A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013